chromosome 21 open reading frame 58Genealiases: []
Q-omics provides the consensus-scored C21orf58 profile across patient tissues and cancer cell-line models. C21orf58 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C21orf58 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, C21orf58 RNA expression shows 19,662 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where C21orf58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C21orf58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C21orf58 survival associations across molecular data types. C21orf58 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C21orf58 RNA expression–survival associations across cancer types. High C21orf58 expression shows unfavorable associations in KIRC, ACC, MESO, LIHC, LGG and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C21orf58 RNA expression.
This table summarizes C21orf58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C21orf58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C21orf58 shows higher tumor expression in BLCA, KIRP, KIRC, LIHC, HNSC and STAD. The BLCA box plot shows higher C21orf58 RNA expression in tumor versus normal tissue (log2 FC = +1.846, t-test p < 0.001).
This table shows molecular features associated with C21orf58 in patient tissues and cancer cell lines. In patient samples, C21orf58 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C21orf58 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
